Akero Therapeutics, Inc. Soared

Akero Therapeutics, Inc. (AKRO:NASDAQ) rocketted at $33.37, representing a gain of 33.9%. On Tue 30 Jun 20, AKRO:NASDAQ hit a New 2-Week Intraday Low of $22.87. The stock got featured on our News Catalysts scanner on Wed 01 Jul 20 at 11:58 AM in the 'BIOTECH' category. From Tue 16 Jun 20, the stock recorded 50.00% Up Days and 45.45% Green Days

The share price of the company has been moving sideways in recent weeks.

About Akero Therapeutics, Inc. (AKRO:NASDAQ)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate AKR-001 is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.